IL6 and congenital rubella syndrome: Norelli et al.34 have confirmed that monocytes are the main source of IL-6 in CRS in a newborn humanized NSG mouse model, and the depletion of monocytes or the use of the IL-6 receptor antagonist tocilizumab prevents CRS-related symptoms in vivo.